Lagos plans advanced treatments for sickle cell disease

Lagos State’s Commissioner for Health, Prof. Akin Abayomi, has announced plans to enhance treatments and early intervention systems to manage sickle cell disease in the state.

Speaking at the Medical Women’s Association of Nigeria (MWAN) National Executive Council Meeting and Scientific Conference in Lagos, Abayomi, represented by Dr. Bodunrin Osikomaiya of the Lagos State Blood Transfusion Service, emphasized the high incidence of sickle cell disease in Lagos and the need for continued innovation and focus.

The conference, themed “Current Trends in the Management of Sickle Cell Disease,” stated the necessity of improving diagnostic capabilities, increasing the availability of basic treatments, and ensuring comprehensive care for patients.

Abayomi stressed the importance of early diagnosis and intervention, which can significantly improve the quality of life for those affected by sickle cell disease.

He also noted the collaboration between Lagos University Teaching Hospital and the Sickle Cell Foundation Nigeria, which led to the establishment of Lagos’ first comprehensive bone marrow transplant center.

Sickle cell disease (SCD) is a genetic blood disorder that causes severe health complications, including painful episodes, infections, strokes, and chronic anemia, affecting multiple organs throughout a person’s life.

Prof. Obiageli Nnodu, Director of the Centre of Excellence for Sickle Cell Disease Research and Training (CESRTA) in Abuja, called for a shift to evidence-based interventions to reduce the prevalence of sickle cell disease in Nigeria.

She emphasized the need for comprehensive knowledge among healthcare providers, patients, stakeholders, and the public to drive effective advocacy and policy implementation.

Nnodu also noted the limited availability and high cost of hydroxyurea, a standard treatment for sickle cell disease, and stressed the importance of public health awareness and resource mobilization to improve the availability and affordability of treatments.

Prof. Miguel Abboud of the American University of Beirut discussed advancements in early diagnosis, supportive care, and infection management, which have improved survival rates for sickle cell patients.

He mentioned the effectiveness of hydroxyurea in reducing pain crises and improving survival, while noting the development of new drugs to enhance hemoglobin levels.

Dr. Annette Akinsete, CEO of the Sickle Cell Foundation Nigeria, revealed that Nigeria contributes over 50% of the global sickle cell burden, with an estimated 150,000 babies born with the disorder annually, and over 100,000 not surviving past their fifth birthday. She called for increased research and awareness to address sickle cell disorder and achieve sustainable development goals related to health.

Prof. Rosemary Ogu, National President of MWAN, stated that the conference aimed to bridge gaps in sickle cell disease management through education and collaboration among healthcare professionals, patients, caregivers, and the public.